Overview of Sompraz IT

Quick Facts

Property	Description
Active Ingredients	Esomeprazole, Itopride
Form	Oral Hard Capsule (Fixed-Dose Combination)
Pharmacological Class	Proton Pump Inhibitor and Prokinetic Agent
General Purpose	Dual management of acid production and gastrointestinal motility
Origin	Synthetic

What Type of Medicine is Sompraz IT?

Sompraz IT is defined as a synthetic Fixed-Dose Combination (FDC) pharmaceutical preparation that is administered via the oral route, typically as a hard capsule. This product integrates two distinct pharmacological classes to address different aspects of digestive health: a Proton Pump Inhibitor (PPI) and a Prokinetic Agent. Its function contrasts with single-agent therapies by combining both acid-reducing and motility-enhancing components into a single dosage unit. This dual formulation is clinically recognized as a rational strategy for managing complex upper gastrointestinal symptoms that may stem from both excessive acid and compromised stomach movement.

Composition: Esomeprazole and Itopride

The composition of Sompraz IT is established by its active compounds: Esomeprazole and Itopride. Esomeprazole, classified as an S-isomer of omeprazole, functions as the PPI component, working to suppress the production of gastric acid. Itopride serves as the Prokinetic Agent, promoting motility enhancement primarily through its dual mechanism of action. The combination of a PPI with a prokinetic like Itopride is considered a rational approach to managing certain digestive symptoms. This combination is often employed when a patient experiences symptoms like acid reflux or heartburn coupled with a pronounced sensation of early satiety or bloating.

General Purpose: Dual Management of Acid and Motility

The general purpose of Sompraz IT is to achieve simultaneous management of excessive gastric acid and impaired gastrointestinal motility. This formulation is positioned as an advanced strategy for addressing symptoms that involve both the chemical environment and the mechanical function of the stomach. By pairing robust acid suppression with enhanced movement in the upper digestive tract, the medicine facilitates the reduction of acid load while promoting the efficient transit of stomach contents.

Regulatory References

Esomeprazole Monograph (DailyMed)

What side effects are possible with Sompraz IT?

Possible Side Effects and Safety Information

The safety profile of Sompraz IT, a combination of Esomeprazole and Itopride, is based on adverse reactions and safety statements classified by government regulatory authorities.

Adverse Reaction Scope

Classification	Examples of Reactions	Affected System-Organ Classes
Common (e.g., ge 1%)	Headache, Diarrhea, Nausea, Abdominal pain, Flatulence	Gastrointestinal, Nervous System
Uncommon	Leucopenia, Hyperprolactinaemia, Dizziness, Irritability	Endocrine, Blood/Lymphatic, Nervous System
Rare/Not Known	Thrombocytopenia, Jaundice, Rash, Severe Cutaneous Reactions	Hepatobiliary, Skin, Immune System

Serious adverse reactions documented in regulatory sources include Acute Tubulointerstitial Nephritis (TIN), Hepatic failure, and severe hypersensitivity events like Anaphylactic reaction/shock. The label for the Esomeprazole component notes that a patient's symptomatic response does not preclude the presence of underlying gastric malignancy.

Duration-Related Safety Patterns

The regulatory label explicitly links certain risks to long-term use. Daily exposure over multiple years may be associated with Cyanocobalamin (Vitamin B-12) Deficiency. Prolonged and multiple daily dose therapy may also be associated with an increased risk for Bone Fracture (hip, wrist, spine) and the development of Fundic Gland Polyps.

Safety-Related Restrictions

Safety constraints include a contraindication for the Itopride component in conditions where increased gastrointestinal motility could be harmful, such as gastrointestinal hemorrhage, mechanical obstruction, or perforation. Furthermore, specific monitoring is required for older adults and patients with hepatic or renal impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile for the components of Sompraz IT (Esomeprazole and Itopride) by listing recognized clinical presentations and mandating immediate emergency actions. The information below is based strictly on government-authorized prescribing information.

Documented Overdose Manifestations

Suspected overdose may manifest with documented symptoms that are generally non-specific but can be serious. Common presentations include headache, diarrhea, nausea, abdominal pain, flatulence, and dizziness. Potential severe outcomes referenced in official labeling include seizures, confusion, tremor, and potentially life-threatening systemic disturbances such as Hypomagnesemia (low magnesium levels) and tachycardia (abnormal or fast heart rate).

Required Emergency Actions

When an overdose is suspected, regulatory guidance is explicit: immediate medical attention is required. The official instructions mandate that you seek immediate medical attention and contact a doctor or local poison control center right away, or go to the nearest hospital emergency room.

Treatment is defined as symptomatic and supportive, aiming to manage the documented clinical manifestations. Official labeling confirms that for the Esomeprazole component, no specific antidote is known, and dialysis is not expected to remove the drug due to high protein binding. Gastric lavage may be considered as a supportive measure.

Therapeutic Uses of Sompraz IT

What Sompraz IT Treats: Main Uses and Benefits

Sompraz IT is a combination product used for the management of symptoms linked to acid-related and motility-related digestive disorders. The medicine is prescribed to assist in symptom management for conditions that involve both excessive stomach acid and slower movement of contents through the upper digestive tract. It is typically employed in scenarios involving discomfort after eating and acid reflux.

The main indications addressed by this combination include symptomatic gastroesophageal reflux disease (GERD), general indigestion (functional dyspepsia), and instances of delayed gastric emptying. The objective of using this medicine is the relief of associated symptoms such as heartburn, acid regurgitation, stomach discomfort, and bloating. Patients receive the benefit of symptom management to support daily comfort.

Quick Fact: Relief for Stomach Discomfort

Eligibility and Restrictions for Use

Who Can and Cannot Use Sompraz IT?

Sompraz IT (Esomeprazole + Itopride) eligibility is strictly defined by regulatory documents, establishing clear criteria for who can and cannot use the medicine. Use is primarily established for adults and adolescents 12 years of age and older.

Absolute Contraindications

The medicine is prohibited for patients with:

Known hypersensitivity to Esomeprazole, Itopride, or substituted benzimidazoles.
Conditions where increased gastrointestinal motility is harmful, such as GI haemorrhage, mechanical obstruction, or perforation.
Concurrent use of the antiretroviral nelfinavir.
Parkinson's disease or related neurological conditions.

️ Restricted and Not Recommended Use

Population Group	Official Regulatory Status
Children (Below 12 years)	Not recommended; safety/efficacy not established.
Pregnancy/Lactation	Not recommended due to insufficient verified safety data.
Severe Organ Impairment	Caution required in patients with severe hepatic impairment or renal impairment.
Older Adults (≥65)	Caution and close monitoring required.

Furthermore, the possibility of gastric malignancy must be excluded before treatment, as the medicine's effects may mask symptoms of the underlying condition. The overall eligibility profile is defined by these contraindications, age limitations, and conditional restrictions related to physiological status.

What should I know about interactions with other medicines?

Official Interaction Profile

Regulatory documentation establishes specific restrictions and monitoring requirements for co-administering Sompraz IT (Esomeprazole/Itopride) with other products, based on two primary interaction types: changes to drug concentration and modification of gastrointestinal motility.

Classification	Official Constraint / Requirement
Contraindicated Combinations	Co-administration with Nelfinavir and Rilpivirine-containing products is formally prohibited. The use of Clopidogrel and Atazanavir is advised against due to official evidence of reduced exposure to their active components.
Exposure Modification	Esomeprazole may increase the blood levels of medicines metabolized by CYP enzymes, including Methotrexate, Tacrolimus, and Cilostazol. Official labeling requires monitoring for drugs like Digoxin due to increased absorption resulting from reduced stomach acidity.
Motility & Absorption	The Itopride component's effect on gastrointestinal movement may influence the absorption of other orally administered drugs, particularly those with a narrow therapeutic index or sustained-release formulations. Anticholinergic Agents are documented to reduce the motility-enhancing action of Itopride.

Co-administration with enzyme inducers such as Rifampin and St. John's Wort is advised against, as these may lower the systemic exposure of the Esomeprazole component. The medicine is also documented to interfere with certain diagnostic procedures; specifically, it may cause falsely elevated Chromogranin A (CgA) levels, necessitating cessation prior to testing.

Mechanism of Action

Sompraz IT is a co-packaged product comprising esomeprazole and itopride, which act via two distinct pharmacodynamic mechanisms on separate targets.

Esomeprazole

Esomeprazole, an S-enantiomer, acts as a prodrug that accumulates selectively in the acidic secretory canaliculi of gastric parietal cells. In this acidic environment, it undergoes protonation and subsequent conversion to a sulfenamide, its active form. The active sulfenamide metabolite forms a stable, covalent bond with sulfhydryl groups of cysteine residues on the H+/K+-ATPase enzyme (the proton pump) at the luminal surface of the parietal cell. This irreversible inhibition blocks the final transport step in the secretion of hydrogen ions into the gastric lumen, thereby reducing both basal and stimulated gastric acid output.

Itopride

Itopride acts through a dual mechanism in the gastrointestinal tract. It functions as a dopamine D2 receptor antagonist, thereby removing the dopaminergic inhibitory tone on acetylcholine release from the enteric nerve endings. Concurrently, it acts as an acetylcholinesterase (AChE) inhibitor, preventing the enzymatic hydrolysis of released acetylcholine. The resulting increase in synaptic acetylcholine concentration enhances the activation of muscarinic receptors on smooth muscle cells. This dual molecular cascade promotes propulsive motility, increases lower esophageal sphincter pressure, and accelerates gastric emptying.

Dosage and Administration Information

How to use Sompraz IT — Administration Guidelines

Sompraz IT (which contains the active ingredient Esomeprazole, a proton pump inhibitor) must be used strictly according to the regimen prescribed by a physician and based on instructions for its delayed-release formulation.

Administration Protocol

Administration scope	Administration Rules
Route of administration	Oral (by mouth).
Dosing schedule (typical)	Once daily, though twice daily dosing may be required for specific conditions such as Zollinger-Ellison Syndrome.
Timing in relation to meals	Must be taken at least one hour before a meal.
Preparation requirements	The delayed-release capsule must be swallowed whole with water. It must not be crushed, chewed, or broken to preserve the enteric-coated granules.
Age-group rules	Use in children is restricted; for some conditions, administration may be limited to patients 12 years and older, while certain forms have weight-based dosing for children as young as 1 month. The specific product labeling must be followed.
Missed-dose rules	If a dose is missed, take it as soon as remembered, unless it is close to the time for the next scheduled dose (e.g., less than 12 hours until the next dose for once-daily regimens). Do not double the dose.

Procedural Structure

Classification	Detail
Administration method type	Oral, Delayed-Release Capsule.
Frequency pattern	Daily (Once or Twice).
Basis of formulation	Based on pharmaceutical monographs.
Use-context constraints	Must be taken before a meal. A dose reduction (typically to 20 mg once or twice daily) is recommended for patients with severe liver impairment (Child-Pugh Class C).

Step Sequence:

Take the prescribed dose once daily, preferably in the morning.
Take the capsule at least one hour before consuming any food.
Swallow the capsule whole with a drink of water.
Do not crush, chew, or open the capsule, as this compromises the delayed-release formulation.

This structure ensures the correct oral administration of the delayed-release formulation, which is crucial for the drug's intended action, and details necessary procedural steps and dosing constraints.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sompraz IT

Evidence for Symptomatic Gastroesophageal Reflux Disease (GERD) Studies

Research exploring the use of this combination medicine for GERD primarily involves short-term Randomized Controlled Trials (RCTs) and subsequent Systematic Reviews. These studies were designed to compare the dual therapy (combining a Proton Pump Inhibitor like Esomeprazole with a Prokinetic Agent like Itopride) against taking the PPI component alone. Researchers focused on patient-reported outcomes describing perceived discomfort, such as the measurement of symptom intensity and frequency, over defined time intervals.

Studies report how symptoms evolved in the observed populations. Some studies reported that the combined approach was observed to be associated with patterns of symptom change that differed from patterns observed with PPI monotherapy. Findings were mixed across studies, with outcomes varying depending on the specific prokinetic agent used. The evidence contributes to understanding short-term symptom patterns in conditions characterized by fluctuating manifestations.

Evidence for Symptoms Unresponsive to Single-Agent Therapy

Research has also explored the use of the combination for GERD symptoms that persist or return despite a patient having taken a standard single-agent PPI treatment. Research examined this clinical situation using various designs, including smaller Observational Add-on Studies and Retrospective Studies. The studies monitored changes in the intensity of persistent reflux-related symptoms and patient global assessments of their condition.

Findings indicate that adding the prokinetic agent was observed in some studies to be associated with patterns of symptom change in the severity of symptoms in previously non-responding patients. However, the evidence is limited, as the studies are often smaller and based on observational settings rather than large, standardized trials.

Research Gaps and Areas of Uncertainty

The evidence highlights what is known and what is still uncertain. Long-term effects are not fully established; the majority of trials focused on short-term changes lasting 4 to 12 weeks, meaning data are still emerging regarding the effects of continued use. For the fixed-dose combination specifically, comparative evidence is lacking in large-scale RCTs against other established dual therapies, and research is ongoing to clarify which specific patient population was associated with the most noticeable change in symptoms.

Frequently Asked Questions (FAQ)

Common questions about Sompraz IT (FAQ)

Q: Why is this drug sometimes used for problems other than acid reflux?

Regulatory documents indicate that the Esomeprazole component is also approved to manage conditions like Zollinger-Ellison syndrome and to reduce the risk of gastric ulcers associated with NSAID use. Additionally, the Itopride component is indicated for relieving various gastrointestinal symptoms of chronic gastritis, such as bloating, nausea, and epigastric pain.

Q: How quickly can I expect Sompraz IT to start working?

The two components work at different speeds. Official information for the Esomeprazole component suggests that the full acid-reducing effect may take between one and four days, as it is not for immediate relief. Conversely, the Itopride component acts faster, with maximum concentrations typically reached within 30 to 45 minutes of administration.

Q: Do I need to change my diet while using Sompraz IT?

Official patient information does not mandate specific, complete dietary changes. However, authoritative sources suggest that avoiding foods known to worsen indigestion, such as rich, spicy, or fatty items, may help manage symptoms. Reducing consumption of alcohol and caffeinated drinks is also generally recommended. If symptoms persist or worsen, patients should seek guidance from their doctor.

Q: Does Sompraz IT interact with common pain relievers?

Regulatory documents mention the relationship between the Esomeprazole component and common pain relievers classified as NSAIDs (Non-Steroidal Anti-Inflammatory Drugs). This component is specifically indicated to help reduce the risk of gastric ulcers that can be associated with continuous NSAID therapy. Official information addresses these specific co-administrations.

Q: How long does the effect of one dose of Sompraz IT usually last?

The components of the medicine have different actions. The half-life of the Itopride component is about six hours. The Esomeprazole component is a Proton Pump Inhibitor, which acts by irreversibly blocking the acid-producing pumps. This mechanism provides a prolonged acid-reduction effect that supports the usual once-daily dosing regimen.

Q: Is Sompraz IT a prescription-only medicine?

The drug's classification depends on its components. The Esomeprazole component is available both by prescription and in lower strengths over-the-counter (OTC). However, the Itopride component, and therefore the fixed-dose combination product (Sompraz IT), is typically classified as a prescription-only medicine in most regions.

Q: Can Sompraz IT affect my sleep?

Official adverse reaction data includes potential effects on the nervous system. Regulatory documents for the Esomeprazole component have listed somnolence (drowsiness) as a reported reaction, particularly in pediatric patients. The Itopride component may also cause fatigue or drowsiness.

Q: What if I accidentally take more Sompraz IT than intended?

If a patient takes more than the prescribed or intended amount, official guidance recommends contacting a doctor or local poison control center immediately. Emergency evaluation may be advised in certain situations.

Q: Do the side effects of Sompraz IT go away over time?

According to patient information, common and mild side effects, such as a headache or mild diarrhea, often do not require medical intervention and may resolve on their own as the body adjusts to the medicine. If side effects persist, worsen, or become bothersome, patients are advised to seek guidance from their doctor.

Q: Can I stop taking Sompraz IT suddenly?

Regulatory guidance, such as that provided in the FDA Medication Guide, advises patients to avoid changing their dose or stopping the medication abruptly. The decision to stop taking this medicine is typically made in consultation with the prescribing doctor.

Q: Does alcohol consumption affect how Sompraz IT works?

Official sources indicate that alcohol does not directly alter how the medicine's components function in the body. However, consuming alcohol can stimulate the stomach to produce more acid. For this reason, alcohol intake may counteract the intended therapeutic effects and potentially worsen existing symptoms.

Q: What are the official recommendations for length of treatment with Sompraz IT?

The length of treatment varies depending on the medical condition. For the Itopride component, clinical studies often follow a duration of up to eight weeks. For the Esomeprazole component, recommended durations for uses like healing erosive esophagitis commonly range from four to eight weeks.

Q: What happens when I finish the full course of Sompraz IT?

If the medicine was taken for frequent heartburn (referring to the OTC use of the PPI component), official guidance states that the 14-day course may be repeated. However, a course should not be taken more often than every four months without consulting a healthcare professional.

Q: Is Sompraz IT used for indigestion?

Yes, official authoritative sources confirm that the Esomeprazole component is widely used to manage symptoms related to indigestion and heartburn. The Itopride component, a prokinetic, is also indicated for symptoms of chronic gastritis, which includes dyspepsia, a term for indigestion.

Q: What is the maximum amount of time Sompraz IT is recommended for continuous use?

The maximum recommended continuous use varies by component and indication. The Itopride component is often capped at eight weeks in clinical use. For the Esomeprazole component, long-term conditions like maintenance therapy or NSAID ulcer risk reduction may permit continuous use for up to six months, strictly under medical supervision.

Q: Is there a generic version of Sompraz IT available?

The active ingredients are well-established. Generic versions of the single Esomeprazole component are widely available, as indicated by FDA guidance documents. The availability of a generic for the specific fixed-dose combination product (Sompraz IT) depends on its individual regulatory and patent status in each market.

Q: Are there different strengths of Sompraz IT available?

Yes, the individual components are available in different strengths. For example, the Esomeprazole component is commonly found in 20 mg and 40 mg dosages. The fixed-dose combination product is typically formulated in specific ratios (such as 40 mg Esomeprazole with 150 mg Itopride), though specific regional variations may exist.

Q: Does Sompraz IT have any warnings related to driving or operating machinery?

The official safety information includes warnings related to driving and operating machinery. Since the medicine may cause side effects such as dizziness or drowsiness, patients who experience these effects are cautioned against driving or operating heavy machinery.

Q: Can Sompraz IT be used to prevent future acid-related problems?

The Esomeprazole component does have established preventative uses. Official product labeling indicates that it is specifically used for the maintenance of healing of erosive esophagitis and to reduce the risk of gastric ulcers associated with continuous therapy using NSAID medications.

Q: What does official information say about discontinuing Sompraz IT?

Official guidance consistently advises against sudden cessation. Patients should not stop taking this medicine without first discussing it with their doctor. The prescribing physician will provide guidance on safe discontinuation.

How should Sompraz IT be stored and disposed of?

Storage and Disposal Conditions for Sompraz IT

Sompraz IT must be stored under conditions that maintain the stability of its components.

Storage Requirements

Condition	Requirement (Official Labeled)
Temperature	Controlled Room Temperature (20 to 25 C), with excursions permitted up to 30 C.
Protection	Store in a cool and dry place, protected from direct sunlight.
Container	Keep the tight, light-resistant container tightly closed.
Child Safety	Store the product out of the sight and reach of children and pets.

Disposal Guidelines

Unused or expired Sompraz IT should be disposed of through a dedicated drug take-back program. If no program is available, the product may be disposed of in the household trash by mixing the capsules with an unappealing substance (like used coffee grounds or dirt), sealing the mixture in a bag, and discarding it. This medicine is not classified as hazardous waste, and it should not be flushed down a toilet or poured down a sink.

Sompraz IT